1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Medpace Holdings, Inc.

Medpace Holdings, Inc.

MEDP
Medpace Holdings, Inc.US flagNASDAQ Global Select
535.41
USD
-2.32
- -
15.29BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.12
- -
9.06
11.81
11.17
19.82
24
25.98
31.85
45.08
61.38
68.13
87.72
94.41
Basic EPS, GAAP
0.65
- -
-0.22
0.38
1
2.06
2.8
4.08
5.07
7.58
9.21
13.06
15.64
16.23
Free Cash Flow per Basic Share
2.44
- -
2
2.19
2.18
3.95
5.13
6.38
6.55
10.84
12.91
18.49
23.64
25.9
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-0.57
-0.26
-3.07
-1.16
1.91
3.24
6.56
-11.1
-7.2
0.27
-15.94
-11.84
Tangible Book Value per Share
- -
- -
-10.96
-5.22
-6.56
-3.95
0.27
2.72
6.95
-9.7
-4.53
4.16
-8.21
-3.43
Basic Weighted Avg Shares
38
- -
40
36
39
36
36
36
36
32
31
31
29
28
Sales/Revenue/Turnover
273
- -
359
422
436
705
861
926
1,142
1,460
1,886
2,109
2,530
2,678
Operating Margin (%)
21.57
- -
8.32
12.45
14.87
14.34
14.78
18.04
17.39
19.09
17.86
21.19
21.14
21.02
Depreciation Expense
31
- -
70
58
46
39
23
20
21
22
26
29
28
28
Net Income, GAAP
25
- -
-9
13
39
73
100
145
182
245
283
404
451
460
Effective Tax Rate (%)
36.53
- -
- -
38.86
31.3
22.1
19.54
13.74
9.91
13.25
15.75
15.03
16.82
19.48
Profit Margin (%)
9.1
- -
-2.42
3.18
8.97
10.39
11.67
15.7
15.92
16.81
15
19.17
17.83
17.19
Working Capital
- -
- -
-39
-35
-63
-79
-26
34
134
-470
-331
-75
-354
-206
LT Debt
- -
492
378
151
205
80
45
115
131
139
142
126
114
122
Total Equity
- -
402
413
611
504
590
726
806
953
386
559
826
459
598
Return on Invested Capital (%)
- -
- -
- -
4.1
5.94
11.29
14.21
17.03
17.85
29.14
44.47
45.94
58.37
62.91
Return on Capital (%)
- -
- -
- -
9.92
34.62
113.5
133.58
84.43
60.92
250.81
-226.37
1,457.46
-426.9
-258.41
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
157.98
103.64
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
119
114
122
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
29
Market Capitalization
15,177
16,206
13,622

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
737
990
1,139
Cash, Cash Equivalents & STI
285
497
653
Accounts Receivable, Net
362
377
370
Inventories
- -
- -
- -
Total Current Liabilities
1,284
1,344
1,345
Payables & Accruals
312
356
379
ST Debt
- -
- -
- -
Deferred Revenue
834
854
856

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.82%
1.36%
-44.39%
Free Cash Flow
25.61%
25.83%
19.15%
Net Income, GAAP
23.55%
25.96%
11.56%
Sales/Revenue/Turnover
22.43%
22.43%
19.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
511
528
533
537
2,109
2025
559
603
660
708
2,530
2026
707
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.33
2.85
3.11
3.78
13.06
2025
3.77
3.16
3.95
4.78
15.64
2026
4.35
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
August James Troendle
Full Time Employees
6,200
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
5375 Medpace Way Cincinnati OH United States of America 45227
IPO Date
Aug 11, 2016
CIK
0001668397
Website
medpace.com
Similar Companies
Sapporo Clinical Laboratory Inc. (9776.T)
Mettler-Toledo International Inc. (MTD)
Access Bio Inc (950130.KS)
AccuStem Sciences Limited (ACMSY)
Cosmo Bio Company,Limited (3386.T)
Clearbridge Health Limited (1H3.SI)
Business
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries; core offerings encompass clinical trial management, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory services including central laboratories, bioanalytical laboratory, imaging core lab, ECG core lab, and Phase I clinical unit; the company operates its proprietary ClinTrak clinical trial management system to integrate study data and enhance efficiency. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace conducts operations across North America, Europe, Latin America, Asia Pacific, South America, Africa, and Australia, with a focus on complex trials in therapeutic areas such as oncology, cardiology, neurology, and infectious diseases, primarily serving small- to mid-sized biotech clients. In recent developments, the company reported record net new business awards of $789.6 million in Q3 2025, a 47.9% increase year-over-year, driving a net book-to-bill ratio of 1.20 and prompting upward revisions to 2025 revenue guidance to $2.48-$2.53 billion, reflecting 17.6%-20.0% growth over 2024 amid strong backlog momentum exceeding $3 billion; Medpace also projects low double-digit revenue growth and high single-digit EBITDA expansion for 2026, supported by strategic emphases on AI-enabled decentralized trials, oncology, and Phase III studies.

Company News

APIChatGPT

  • zacks.com

    CON vs. MEDP: Which Stock Is the Better Value Option?

  • zacks.com

    Why Medpace (MEDP) Dipped More Than Broader Market Today

  • gurufocus.com

    A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF Value $503.39 vs Price $546.29

  • zacks.com

    Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

  • zacks.com

    Medpace Stock Outlook Turns on Backlog Quality and Cancellations

  • zacks.com

    Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

  • zacks.com

    CON or MEDP: Which Is the Better Value Stock Right Now?

  • zacks.com

    Medpace (MEDP) Advances While Market Declines: Some Information for Investors

  • gurufocus.com

    Is It Too Late to Buy Medpace Holdings Inc (MEDP) After 3.9% Rally? GF Value Says Undervalued

  • zacks.com

    Medpace (MEDP) Suffers a Larger Drop Than the General Market: Key Insights

  • businesswire.com

    Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

  • zacks.com

    CON vs. MEDP: Which Stock Is the Better Value Option?

  • zacks.com

    Why the Market Dipped But Medpace (MEDP) Gained Today

  • prnewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • businesswire.com

    MEDP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Medpace (MEDP) Investors of Securities Class Action Deadline on June 8, 2026

  • newsfilecorp.com

    MEDPACE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action - MEDP

  • globenewswire.com

    Safirstein Law LLC Announces That A Class Action Lawsuit Has Been Filed Against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP)

  • gurufocus.com

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Highlights Class Action Against Medpace Holdings (MEDP) and Upcoming Lead Plaintiff Deadline of June 8, 2026

  • businesswire.com

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Highlights Class Action Against Medpace Holdings (MEDP) and Upcoming Lead Plaintiff Deadline of June 8, 2026

  • newsfilecorp.com

    INVESTOR DEADLINE: Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit